344 related articles for article (PubMed ID: 23800665)
1. Protection of dopaminergic neurons by 5-lipoxygenase inhibitor.
Kang KH; Liou HH; Hour MJ; Liou HC; Fu WM
Neuropharmacology; 2013 Oct; 73():380-7. PubMed ID: 23800665
[TBL] [Abstract][Full Text] [Related]
2. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
3. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease.
Pariyar R; Bastola T; Lee DH; Seo J
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216503
[TBL] [Abstract][Full Text] [Related]
5. Secalonic acid A protects dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP⁺)-induced cell death via the mitochondrial apoptotic pathway.
Zhai A; Zhu X; Wang X; Chen R; Wang H
Eur J Pharmacol; 2013 Aug; 713(1-3):58-67. PubMed ID: 23665112
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
[TBL] [Abstract][Full Text] [Related]
7. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity.
Oeckl P; Ferger B
Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection by Paeoniflorin in the MPTP mouse model of Parkinson's disease.
Zheng M; Liu C; Fan Y; Yan P; Shi D; Zhang Y
Neuropharmacology; 2017 Apr; 116():412-420. PubMed ID: 28093210
[TBL] [Abstract][Full Text] [Related]
9. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Choi DY; Lee MK; Hong JT
Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
[TBL] [Abstract][Full Text] [Related]
10. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
[TBL] [Abstract][Full Text] [Related]
11. Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress.
Huang HJ; Wang YT; Lin HC; Lee YH; Lin AM
Mol Neurobiol; 2018 Jan; 55(1):138-144. PubMed ID: 28822080
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH
Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death.
Borrajo A; Rodriguez-Perez AI; Villar-Cheda B; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Oct; 85():1-8. PubMed ID: 24878243
[TBL] [Abstract][Full Text] [Related]
14. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Wang QM; Xu YY; Liu S; Ma ZG
Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
[TBL] [Abstract][Full Text] [Related]
15. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of madecassoside in early stage of Parkinson's disease induced by MPTP in rats.
Xu CL; Qu R; Zhang J; Li LF; Ma SP
Fitoterapia; 2013 Oct; 90():112-8. PubMed ID: 23876367
[TBL] [Abstract][Full Text] [Related]
17. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures.
Schmidt DE; Ebert MH; Lynn JC; Whetsell WO
J Neural Transm (Vienna); 1997; 104(8-9):875-85. PubMed ID: 9451719
[TBL] [Abstract][Full Text] [Related]
19. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
[TBL] [Abstract][Full Text] [Related]
20. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice.
Kato H; Kurosaki R; Oki C; Araki T
Brain Res; 2004 Dec; 1030(1):66-73. PubMed ID: 15567338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
